Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs

This study has been completed.
Sponsor:
Collaborators:
Zorgverzekeraar CZ
Scientific Institute for Dutch Pharmacists, The Netherlands
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
NCT00509717
First received: February 28, 2007
Last updated: July 9, 2008
Last verified: July 2008

February 28, 2007
July 9, 2008
October 2006
February 2008   (final data collection date for primary outcome measure)
The percentage of selected (=undertreated) patients receiving at least one prescription for lipid-lowering medication. [ Time Frame: six months after the general practitioner received the list with selected patients ] [ Designated as safety issue: No ]
The percentage of selected (=undertreated) patients receiving at least one prescription for lipid-lowering medication in the six months after the general practitioner received the list with selected patients.
Complete list of historical versions of study NCT00509717 on ClinicalTrials.gov Archive Site
Differences in prescribing for age categories and co-medication. [ Time Frame: six months ] [ Designated as safety issue: No ]
  • Choice and dosage of newly prescribed lipid-lowering medication.
  • Differences in prescribing for age categories and co-medication.
Not Provided
Not Provided
 
Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs
Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs. A Randomized Trial.

The purpose of this study is to determine the effectiveness of maximal support of community pharmacies to implement a pharmaceutical care model for improving underprescription and treatment persistence regarding lipid-lowering medication in patients with cardiovascular disease.

Cardiovascular disease is the main cause of death in large parts of the world. Next to life style changes, pharmaceutical treatment is a keystone in the treatment of cardiovascular disease. Despite the strong evidence for the effectiveness of lipid-lowering therapy, less than half of the people eligible are treated. With specific medication searches in the community pharmacy database, an easy tool for detecting patients who are undertreated is available. Based on this tool, a pharmaceutical care model for improving underprescription and treatment persistence regarding lipid-lowering medication in patients with cardiovascular disease was constructed.

Moreover, it is not known yet how to implement this pharmaceutical care model in community pharmacies effectively. With multifaceted interventions the behaviour of health professionals can be changed. In this study the effectiveness of a maximal support strategy, including interactive educational meetings, reminders, audit and feedback, is compared to a minimal implementation strategy.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Cardiovascular Diseases
  • Other: intensive implementation programme
    educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
  • Other: control
    educational manual
  • Experimental: experimental
    Intervention: Other: intensive implementation programme
  • Active Comparator: control
    Intervention: Other: control

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
March 2008
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • pharmacies: resident in the south of the Netherlands
  • patients: with antiplatelet therapy and without lipid-lowering medication

Exclusion Criteria:for patients:

  • terminal disease
  • severe mental disorder
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00509717
WOK/WINAp/CZ-02
No
Caroline van de Steeg-van Gompel, Scientific Institute for Quality of Healthcare
Radboud University
  • Zorgverzekeraar CZ
  • Scientific Institute for Dutch Pharmacists, The Netherlands
Principal Investigator: Peter G. de Smet, PhD Radboud University
Study Director: Michel Wensing, PhD Scientific Institute for Quality of Healthcare
Radboud University
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP